Interplay between m6A RNA methylation and ferroptosis in diabetes development and therapy N6-methyladenosine (m6A), a common RNA modulator, can affect critical genes related to ferroptosis, including cyclin-dependent kinase inhibitor 1A (CDKN1A), myo-inositol oxygenase (MIOX), proto-oncogene, BHLH transcription factor (MYCN), and cluster of differentiation 82 (CD82)
Large-scale human studies and regulatory reviews have not identified increased cancer risk, including breast cancer, with GLP-1 receptor agonists
The secondary outcomes were all-cause death, heart failure admission, admission due to any cause, composite major adverse limb events including newly diagnosed peripheral arterial disease, claudication, clinical limb ischemia, limb revascularization or amputation, hypoglycemia, diabetic ketoacidosis (DKA) or hyperosmolar hyperglycemic state (HHS), and infection death
This allows for faster detox support, stronger immune defense, improved respiratory function, and noticeable improvements in skin clarity and tone with continued use
